Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


Potential of bacteriophage ΦAB2 as an environmental biocontrol agent for the control of multidrug-resistant Acinetobacter baumannii.

Chen LK, Liu YL, Hu A, Chang KC, Lin NT, Lai MJ, Tseng CC.

BMC Microbiol. 2013 Jul 8;13:154. doi: 10.1186/1471-2180-13-154.


Isolation and characterization of ZZ1, a novel lytic phage that infects Acinetobacter baumannii clinical isolates.

Jin J, Li ZJ, Wang SW, Wang SM, Huang DH, Li YH, Ma YY, Wang J, Liu F, Chen XD, Li GX, Wang XT, Wang ZQ, Zhao GQ.

BMC Microbiol. 2012 Jul 28;12:156. doi: 10.1186/1471-2180-12-156.


Isolation and characterization of a virulent bacteriophage AB1 of Acinetobacter baumannii.

Yang H, Liang L, Lin S, Jia S.

BMC Microbiol. 2010 Apr 29;10:131. doi: 10.1186/1471-2180-10-131.


Antibacterial activity of Acinetobacter baumannii phage ϕAB2 endolysin (LysAB2) against both gram-positive and gram-negative bacteria.

Lai MJ, Lin NT, Hu A, Soo PC, Chen LK, Chen LH, Chang KC.

Appl Microbiol Biotechnol. 2011 Apr;90(2):529-39. doi: 10.1007/s00253-011-3104-y.


Infection Control Programs and Antibiotic Control Programs to Limit Transmission of Multi-Drug Resistant Acinetobacter baumannii Infections: Evolution of Old Problems and New Challenges for Institutes.

Chen CH, Lin LC, Chang YJ, Chen YM, Chang CY, Huang CC.

Int J Environ Res Public Health. 2015 Jul 30;12(8):8871-82. doi: 10.3390/ijerph120808871. Review.


Isolation and characterization of phi AB2: a novel bacteriophage of Acinetobacter baumannii.

Lin NT, Chiou PY, Chang KC, Chen LK, Lai MJ.

Res Microbiol. 2010 May;161(4):308-14. doi: 10.1016/j.resmic.2010.03.007.


Risk factors of multidrug resistance in nosocomial bacteremia due to Acinetobacter baumannii: a case-control study.

Shih MJ, Lee NY, Lee HC, Chang CM, Wu CJ, Chen PL, Ko NY, Ko WC.

J Microbiol Immunol Infect. 2008 Apr;41(2):118-23.


Characterization, sequencing and comparative genomic analysis of vB_AbaM-IME-AB2, a novel lytic bacteriophage that infects multidrug-resistant Acinetobacter baumannii clinical isolates.

Peng F, Mi Z, Huang Y, Yuan X, Niu W, Wang Y, Hua Y, Fan H, Bai C, Tong Y.

BMC Microbiol. 2014 Jul 5;14:181. doi: 10.1186/1471-2180-14-181.


Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection.

Shin JA, Chang YS, Kim HJ, Kim SK, Chang J, Ahn CM, Byun MK.

Yonsei Med J. 2012 Sep;53(5):974-84. doi: 10.3349/ymj.2012.53.5.974.


Effect of a novel podophage AB7-IBB2 on Acinetobacter baumannii biofilm.

Thawal ND, Yele AB, Sahu PK, Chopade BA.

Curr Microbiol. 2012 Jul;65(1):66-72. doi: 10.1007/s00284-012-0127-2.


Eradication of multidrug-resistant Acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate: a matched case-control study.

Kuo SC, Lee YT, Yang SP, Chen CP, Chen TL, Hsieh SL, Siu LK, Fung CP.

Clin Microbiol Infect. 2012 Sep;18(9):870-6. doi: 10.1111/j.1469-0691.2011.03682.x.


Isolation and characterization of wide host range lytic bacteriophage AP22 infecting Acinetobacter baumannii.

Popova AV, Zhilenkov EL, Myakinina VP, Krasilnikova VM, Volozhantsev NV.

FEMS Microbiol Lett. 2012 Jul;332(1):40-6. doi: 10.1111/j.1574-6968.2012.02573.x.


Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains.

Ye JJ, Huang CT, Shie SS, Huang PY, Su LH, Chiu CH, Leu HS, Chiang PC.

PLoS One. 2010 Apr 1;5(4):e9947. doi: 10.1371/journal.pone.0009947.


Control of multi-drug-resistant Acinetobacter baumannii outbreaks in an intensive care unit: feasibility and economic impact of rapid unit closure.

Ayraud-Thévenot S, Huart C, Mimoz O, Taouqi M, Laland C, Bousseau A, Castel O.

J Hosp Infect. 2012 Dec;82(4):290-2. doi: 10.1016/j.jhin.2012.08.016.


Atomic force microscopy analysis of the Acinetobacter baumannii bacteriophage AP22 lytic cycle.

Dubrovin EV, Popova AV, Kraevskiy SV, Ignatov SG, Ignatyuk TE, Yaminsky IV, Volozhantsev NV.

PLoS One. 2012;7(10):e47348. doi: 10.1371/journal.pone.0047348.


Multidrug-resistant Acinetobacter baumannii isolates in pediatric patients of a university hospital in Taiwan.

Chang PY, Hsueh PR, Wu PS, Chan PC, Yang TT, Lu CY, Chang LY, Chen JM, Lee PI, Lee CY, Huang LM.

J Microbiol Immunol Infect. 2007 Oct;40(5):406-10.


Susceptibility patterns and molecular epidemiology of multidrug-resistant Acinetobacter baumannii strains from three military hospitals in China.

Yan ZQ, Shen DX, Cao JR, Chen R, Wei X, Liu LP, Xu XL.

Int J Antimicrob Agents. 2010 Mar;35(3):269-73. doi: 10.1016/j.ijantimicag.2009.10.016.


Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome.

Kuo LC, Lai CC, Liao CH, Hsu CK, Chang YL, Chang CY, Hsueh PR.

Clin Microbiol Infect. 2007 Feb;13(2):196-8.


Multidrug-resistant Acinetobacter baumannii in ventilator-associated pneumonia at a medical center in southern Taiwan.

Mai MH, Tsai HC, Lee SS, Wang YH, Chen YS, Wann SR, Liu YC.

J Microbiol Immunol Infect. 2007 Oct;40(5):401-5.


Activity of a dry mist-generated hydrogen peroxide disinfection system against methicillin-resistant Staphylococcus aureus and Acinetobacter baumannii.

Piskin N, Celebi G, Kulah C, Mengeloglu Z, Yumusak M.

Am J Infect Control. 2011 Nov;39(9):757-62. doi: 10.1016/j.ajic.2010.12.003.

Items per page

Supplemental Content

Support Center